INFORMATION DISCLOSURE

Filing Date April 23, 2004 First Named Inventor Gadde, Kishore M.

STATEMENT BY APPLICANT (Multiple sheets used when necessary)

SHEET 1 OF 2

Unassigned P

OREX.009C1

t i

10/830,071

Art Unit Examiner Unassigned i

JAN 3 1 2025 H

6				U.S. PATENT I	U.S. PATENT DOCUMENTS		
TRADFIMET Initials		Cite No.	I NUMBER - KINN I INDE IN KNOWN) I	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
H		1	4,172,896	10/1979	Uno et al		
0		2	4,513,006	4/1985	Marayanoff et al		
		3	6,071,537	6/2000	Shank		
		4	6,191,117	2/2001	Kozachuk		
		5	6,323,236	11/2001	McElroy		
		6	6,506,799	1/2003	Dasseux		
	/	7	6,548,551	4/2003	Hinz		
	7	8	20040029941	2/2004	Jennings		

Application No.

Attorney Docket No.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
W	9	WO 03/092682	11/2003	WIPO		

7		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	Ayala, "Weight Loss Associated With the Administration of Zonisamide", AES Proceedings, Epilepsia 41(Suppl. 7):99 (2000) –No.2.041	
()	11	Ayala et al, "Weight Loss Associated With the Administration of Zonisamide", A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, December 1-6, 2000, Los Angeles, California	
	12	Gadde et al, "Zonisamide for Weight Loss in Obese Adults – A Randomized Controlled Trial", JAMA 289(14):1820-1825 (2003)	
	13	Gadde et al, "Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women", Obesity Research 9(9):544-551 (2001)	
	14	Gadde et al, "Randomized Controlled Trial of Zonisamide for Treating Obesity", American Epilepsy Society, http://164.109.45.39/submission/aes/status/\preview.full.asp?presid=2%2E258 , September 11, 2002	
	15	Gadde et al, "Randomized Trial of Weight Loss Efficacy of Zonisamide", No. 304, 26(Suppl. 1), August 2002, International Journal of Obesity and Related Metabolic Disorders, Journal of the International Association for the Study of Obesity, Ninth International Congress on Obesity, Sao Paolo, Brazil, August 24-29, 2002	
\mathcal{J}	16	Gadde et al, "Zonisamide in/Obesity: A 16-Week Randomized Trial", No. NR473, New Research, American Psychiatric Association 2002 Annual Meeting, May 18-23, 2002, Philadelphia, Pennsylvania	

	<u> </u>	1		<u> </u>	1		
Examiner Signature	War	line Cotaver	Date Considered 4	1	1	Ó	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

٨

T1 - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

		Application No.	10/830,071
	INFORMATION DISCLOSURE	Filing Date	April 23, 2004
	STATEMENT BY APPLICANT	First Named Inventor	Gadde, Kishore M.
	STATEMENT OF APPLICANT	Art Unit	Unassigned if IV
	(Multiple sheets used when necessary)	Examiner	Unassigned 1. CJIN65
Г	SHEET 2 OF 2	Attorney Docket No.	OREX.009C1

	NON PATENT LITERATURE DOCUMENTS				
Examiner Inițials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹		
W	17	Gadde and Logue, "Bupropion Sustained Release in Obesity: A Randomized Double-Blind, Placebo-Controlled Study", No. NR634, New Research Program & Abstracts, American Psychiatric Association, 1999 Annual Meeting, The Clinician, May 15-20, 1999, Washington, D.C.			
(;)	18	Ginsberg and Sussman, "Effects of Mood Stabilizers on Weight", Primary Psychiatry 7(5):49-58 (2000)			
\overline{V}	19	Grady, "Quest for Weight-Loss Drug Takes an Unusual Turn", The New York Times – Health, www.nytimes.com, March 15, 2003			
	20	Kanios et al, "Compositions and methods for topical administration of pharmaceutically active agents", Database USPT on WEST – USP 5,719,197, February 17, 1998			
	21	Matsuura, "Indication for Anterior Temporal Lobectomy in Patients with Temporal Lobe Epilepsy and Psychopathology", Epilepsia 41(Suppl. 9) :39-42 (2000)			
	22	Morris, III, "The Effect of Zonisamide Administration on Patient Weight", A Scientific Exhibit at the American Epilepsy Society Annual Meeting, December 3, 2000, Los Angeles, California			
	23	Walker et al, "Chronic Toxicity of the Anticonvulsant Zonisamide in Beagle Dogs", Fundamental and Applied Toxicology 11:333-342 (1988)	· · · · · · · · · · · · · · · · · · ·		
	/ 24	Welty et al, "Weight Loss Associated With Use of Zonisamide in European and US Clinical Trials", A Compendium of Posters and Platform Sessions for Zonegran®, Presented at the Annual Meeting 2001 of the American Epilepsy Society, November 30 – December 5, 2001, Philadelphia, Pennsylvania			
V	25	Wilner, "Is Weight Loss With Zonisamide Gender-Specific?", Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society, https://secure.neurohub.net/cgi-perl/get.cgi?pub=52318&ext=htm			

S:\DOCS\SKT\SKT-5879.DOC 012105

Examiner Signature

Date Considered

PExaminer: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.